Weight management medicine is moving faster than almost any other field in clinical practice. Just a few years ago, the best pharmacological tools available for obesity offered 5–8% total body weight loss. Then tirzepatide arrived, and suddenly 20% was achievable. Now, early data on retatrutide — a drug that adds a third receptor target to the formula — is pushing that figure higher still. But “higher numbers” in a Phase 2 trial and “better medicine” for your patients are not

You were losing steadily. The appetite suppression was working, the scale was moving, and the results felt almost effortless compared to everything you had tried before. Then, somewhere around month four or five, it stopped. The number on the scale has not changed in three weeks. Maybe four. You are still injecting on schedule, you have not changed your diet dramatically, and you are starting to wonder: has tirzepatide stopped working for me? It is one of the most common ques